EPRX
EUPRAXIA PHARMACEUTICALS INC.
$6.04
+0.17%
$394.6M
No data for this timeframe.
Vol
Market Cap$394.6M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders22 funds
Inst. Value$42.4M
Inst. Activity4 buys / 1 sells
SEC Reports6
Press Releases2
Recent Activity
May 29, 2026
SEC
Eupraxia Pharmaceuticals filed its management information circular and proxy materials for the upcoming annual general m
6-K — Impact 3/10
May 29, 2026
SEC
Eupraxia Pharmaceuticals filed a 6-K confirming that proxy-related materials for its upcoming shareholder meeting were m
6-K — Impact 2/10
May 28, 2026
SEC
Eupraxia Pharmaceuticals filed a 6-K announcing management's participation in the Jefferies Global Healthcare Conference
6-K — Impact 2/10
Inst.
Point72 Asset Management, L.P. — ADD
967,575 shares ($7.0M)
Inst.
CIBC WORLD MARKET INC. — DOUBLED
150,950 shares ($1.1M)
May 12, 2026
earnings
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
<p align="center"><em>Robust response in highest dose cohort after 36 weeks following a single treat
Apr 21, 2026
Press
Eupraxia Pharmaceuticals released 36-week data from Cohort 9 of its RESOLVE trial, showing robust and sustained symptom
Impact 8/10
Mar 13, 2026
Press
Eupraxia Pharmaceuticals reported its Q4 2025 financial results, posting a wider net loss of $16.7 million compared to $
Impact 6/10
Price Targets
$16.28
+169.5% upside
Strong Buy
Current $6.04
Low $11.00
Median $15.50
High $25.00
9 analysts
$11.00
$25.00
Analyst Ratings
4Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 21, 2026 | Stifel | INITIATE | Buy |
| May 4, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 22, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 23, 2026 | William Blair | INITIATE | Outperform |
| Mar 17, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.26 ▼ -48.3% | $-0.30 — $-0.22 | 2% YoY | 6 |
| Next Q | $-0.26 ▼ -42.9% | $-0.31 — $-0.22 | -37% YoY | 6 |
| Current FY | $-1.05 ▼ -47.0% | $-1.19 — $-0.91 | -2% YoY | 6 |
| Next FY | $-0.92 ▼ -43.9% | $-1.44 — $0.36 | 12% YoY | 9 |
Latest Reports
NEUTRAL
6-K
3/10
Eupraxia Pharmaceuticals filed its management information circular and proxy materials for the upcoming annual general m
May 29, 2026
NEUTRAL
6-K
2/10
Eupraxia Pharmaceuticals filed a 6-K confirming that proxy-related materials for its upcoming shareholder meeting were m
May 29, 2026
BULLISH
Press
8/10
Eupraxia Pharmaceuticals released 36-week data from Cohort 9 of its RESOLVE trial, showing robust and sustained symptom
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BALYASNY ASSET MANAGEMENT L.P. | $9.8M | — |
| Point72 Asset Management, L.P. | $7.0M | ADD |
| Rubric Capital Management LP | $5.0M | — |
| AMERIPRISE FINANCIAL INC | $3.8M | — |
| Woodline Partners LP | $3.2M | — |
22 institutional holders with $42.4M total value (5,856,748 shares) as of 2026-Q1. Top holders: BALYASNY, Point72, Rubric. Net buying activity: 4 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BALYASNY ASSET MANAGEMENT L.P. | 1,350,000 | $9.8M | 23.1% | — |
| 2 | Point72 Asset Management, L.P. | 967,575 | $7.0M | 16.5% | ADD +35.9% |
| 3 | Rubric Capital Management LP | 691,170 | $5.0M | 11.8% | — |
| 4 | AMERIPRISE FINANCIAL INC | 524,257 | $3.8M | 9.0% | — |
| 5 | Woodline Partners LP | 440,551 | $3.2M | 7.5% | — |
| 6 | Alyeska Investment Group, L.P. | 375,000 | $2.7M | 6.4% | — |
| 7 | BANK OF AMERICA CORP /DE/ | 268,221 | $1.9M | 4.6% | DOUBLED +455.8% |
| 8 | ROYAL BANK OF CANADA | 261,376 | $1.9M | 4.5% | ADD +25.0% |
| 9 | CITADEL ADVISORS LLC | 230,176 | $1.7M | 3.9% | — |
| 10 | MARSHALL WACE, LLP | 158,133 | $1.1M | 2.7% | — |
| 11 | CIBC WORLD MARKET INC. | 150,950 | $1.1M | 2.6% | DOUBLED +160.0% |
| 12 | Hudson Bay Capital Management LP | 92,347 | $668.6K | 1.6% | — |
| 13 | TD Waterhouse Canada Inc. | 81,725 | $589.8K | 1.4% | DOUBLED +751.3% |
| 14 | 1832 Asset Management L.P. | 60,000 | $434.4K | 1.0% | ADD +86.7% |
| 15 | GOLDMAN SACHS GROUP INC | 53,080 | $384.3K | 0.9% | — |
| 16 | RAYMOND JAMES FINANCIAL INC | 50,560 | $366.1K | 0.9% | — |
| 17 | BANK OF MONTREAL /CAN/ | 38,250 | $276.1K | 0.7% | — |
| 18 | TORONTO DOMINION BANK | 32,898 | $237.5K | 0.6% | — |
| 19 | TWO SIGMA INVESTMENTS, LP | 10,800 | $78.2K | 0.2% | — |
| 20 | Aptus Capital Advisors, LLC | 10,500 | $76.0K | 0.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | ADD | 712,104 | 967,575 | +35.9% | $7.0M | 2026-Q1 |
| CIBC WORLD MARKET INC. | DOUBLED | 58,050 | 150,950 | +160.0% | $1.1M | 2026-Q1 |
| TD Waterhouse Canada Inc. | DOUBLED | 9,600 | 81,725 | +751.3% | $589.8K | 2026-Q1 |
| 1832 Asset Management L.P. | ADD | 32,138 | 60,000 | +86.7% | $434.4K | 2026-Q1 |
| NATIONAL BANK OF CANADA /FI/ | TRIM | 586 | 359 | -38.7% | $812.00 | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 45,577 | 253,321 | +455.8% | $1.9M | 2025-Q4 |
| NATIONAL BANK OF CANADA /FI/ | TRIM | 882 | 586 | -33.6% | $4.4K | 2025-Q4 |
| UBS Group AG | DOUBLED | 37,499 | 95,756 | +155.4% | $565.0K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 12,559 | 45,577 | +262.9% | $268.9K | 2025-Q3 |
| ROYAL BANK OF CANADA | ADD | 342,828 | 428,584 | +25.0% | $2.5M | 2025-Q2 |
| UBS Group AG | TRIM | 51,199 | 37,499 | -26.8% | $216.0K | 2025-Q2 |
| TD Waterhouse Canada Inc. | NEAR_EXIT | 104,986 | 9,600 | -90.9% | $55.9K | 2025-Q2 |
| UBS Group AG | ADD | 28,000 | 51,199 | +82.9% | $167.9K | 2025-Q1 |
| NATIONAL BANK OF CANADA /FI/ | DOUBLED | 43 | 764 | +1676.7% | $2.5K | 2025-Q1 |
| NATIONAL BANK OF CANADA /FI/ | TRIM | 150 | 43 | -71.3% | $135.00 | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 4 neutral. Avg impact: 4.2/10.
NEUTRAL
6-K
3/10
Eupraxia Pharmaceuticals filed its management information circular and proxy materials for the upcom
May 29, 2026
NEUTRAL
6-K
2/10
Eupraxia Pharmaceuticals filed a 6-K confirming that proxy-related materials for its upcoming shareh
May 29, 2026
NEUTRAL
6-K
2/10
Eupraxia Pharmaceuticals filed a 6-K announcing management's participation in the Jefferies Global H
May 28, 2026
BEARISH
PRESS-RELEASE
7/10
Eupraxia reported Q1 2026 EPS of -$0.37, a 91.5% miss vs consensus of -$0.19, with net loss widening
May 12, 2026
NEUTRAL
6-K
4/10
Eupraxia Pharmaceuticals announced it will present four abstracts at the Digestive Disease Week (DDW
Apr 22, 2026
BULLISH
6-K
7/10
Eupraxia Pharmaceuticals released 36-week data from the highest dose cohort (Cohort 9, n=3) in the o
Apr 21, 2026
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 4 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$16.28 mean target
+169.5% upside
Strong Buy (3.00)
$11.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $6.04 |
| Target Low | $11.00 |
| Target Mean | $16.28 |
| Target Median | $15.50 |
| Target High | $25.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.26 | $-0.30 | $-0.22 | 1.9% | -48.3% | 0↑ 4↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-0.26 | $-0.31 | $-0.22 | -36.8% | -42.9% | 0↑ 4↓ | $0.0B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-1.05 | $-1.19 | $-0.91 | -2.3% | -47.0% | 0↑ 5↓ | $0.0B | 0.0% | 6 |
| Next FY 2027-12-31 |
$-0.92 | $-1.44 | $0.36 | 12.2% | -43.9% | 1↑ 6↓ | $0.0B | 0.0% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.255 | |
| 7d ago | $-0.260 | +0.005 |
| 30d ago | $-0.172 | -0.083 |
| 60d ago | $-0.160 | -0.095 |
| 90d ago | $-0.160 | -0.095 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 21, 2026 | Stifel | INITIATE | — | Buy |
| May 4, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 22, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 23, 2026 | William Blair | INITIATE | — | Outperform |
| Mar 17, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 15, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Jan 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
<p align="center"><em>Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI</em></p>
May 1, 2026
other
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
<p align="justify">VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ
Apr 22, 2026
routine
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
<p align="justify">VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASD
Apr 21, 2026
fda
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
<p align="justify">VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASD
Mar 13, 2026
earnings
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results